Skip to Content

Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.



Clinical Trials Details

Recurrent or Persistent Low-Grade Serous Cancer of the Ovary, Fallopian Tube or Primary Peritoneum

A Study of MEK162, Recurrent or Persistant Low-Grade Serous Chemotherapy of the Ovary, Fallopian Tube or Primary Peritoneum


Phase 3 randomized,  open-label study will evaluate MEK 162 vs physician choice of selected chemotherapies in patients with low-grade serous carcinoma of the ovaries, fallopian tubes or primary peritneal who have recurrent or persistent disease following:

  • at least 1 prior platinum-based chemotherapy
  • no more than 3 prior lines of chemotherapy
  • Central pathology review of patient histology tumor specimen
IRB Protocol Number
Principal Investigator(s)
Randall Gibb, MD
Array BioPharma Inc.
Judy Miller, RN CCRP at 406-435-7482


  • Billings Clinic Hospital Fountain Courtyard - South of the Hospital Cafeteria
    2750 9th Ave North
    Billings, MT 59101